Survival Benefit of Concurrent Chemoradiotherapy for Advanced Ampulla of Vater Cancer

Overview

Journal World J Clin Cases

Publisher Baishideng Publishing Group

Specialty General Medicine

Date 2024 Feb 5

PMID 38313654

Authors

Chae Hwa Kwon

Hyung Il Seo

Dong Uk Kim

Sung Yong Han

Suk Kim

Nam Kyung Lee

Seung Baek Hong

Ji Hyun Ahn

Young Mok Park

Byeong Gwan Noh

Affiliations

Soon will be listed here.

Abstract

Background: Currently, there is no standard adjuvant therapy for patients with resected ampulla of Vater (AoV) cancer.

Aim: To evaluate the effectiveness of adjuvant concurrent chemoradiotherapy (CCRT) in patients with advanced AoV cancer who underwent curative resection.

Methods: This single-centered, retrospective study included 29 patients with advanced AoV cancer who underwent pancreaticoduodenectomy between 2006 and 2018. The impact of CCRT on advanced AoV cancer was analyzed.

Results: The 1-, 3-, and 5-yr recurrence-free survival (RFS) rates for patients with advanced AoV cancer were 82.8%, 48.3%, and 40.8%, respectively, and the overall survival (OS) rates were 89.7%, 62.1%, and 51.7%, respectively. Lymphovascular invasion was found to be a significant risk factor for RFS and OS in patients with advanced AoV cancer in the univariate analysis, whereas T stage and lymph node metastasis were significantly associated with OS in the multivariate analysis. Compared to the patients who did not receive adjuvant CCRT, those who received adjuvant CCRT did not show statistically significant improvements in the RFS and OS, although they had a significantly lower average age and significantly higher platelet-to-lymphocyte ratio.

Conclusion: Adjuvant CCRT did not improve survival outcomes in patients with advanced AoV cancer. These findings contribute to existing knowledge on the effectiveness of CCRT in this patient population and provide important insights for clinical decision-making.

References

Kwon J, Kim B, Kim K, Chie E, Ha S . Survival Benefit of Adjuvant Chemoradiotherapy in Patients With Ampulla of Vater Cancer: A Systematic Review and Meta-analysis. Ann Surg. 2015; 262(1):47-52. DOI: 10.1097/SLA.0000000000001182. View

Berberat P, Kunzli B, Gulbinas A, Ramanauskas T, Kleeff J, Muller M . An audit of outcomes of a series of periampullary carcinomas. Eur J Surg Oncol. 2008; 35(2):187-91. DOI: 10.1016/j.ejso.2008.01.030. View

Miura J, Jayakrishnan T, Amini A, Johnston F, Tsai S, Erickson B . Defining the role of adjuvant external beam radiotherapy on resected adenocarcinoma of the ampulla of vater. J Gastrointest Surg. 2014; 18(11):2003-8. DOI: 10.1007/s11605-014-2629-7. View

Neoptolemos J, Moore M, Cox T, Valle J, Palmer D, McDonald A . Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012; 308(2):147-56. DOI: 10.1001/jama.2012.7352. View

Nassour I, Hynan L, Christie A, Minter R, Yopp A, Choti M . Association of Adjuvant Therapy with Improved Survival in Ampullary Cancer: A National Cohort Study. J Gastrointest Surg. 2017; 22(4):695-702. PMC: 5890432. DOI: 10.1007/s11605-017-3624-6. View

Kim J, Jeong J, Ryoo B, Kim K, Chang H, Oh D . Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients. Cancer Res Treat. 2020; 53(2):424-435. PMC: 8053873. DOI: 10.4143/crt.2020.953. View

Sakata J, Shirai Y, Wakai T, Yokoyama N, Sakata E, Akazawa K . Number of positive lymph nodes independently affects long-term survival after resection in patients with ampullary carcinoma. Eur J Surg Oncol. 2006; 33(3):346-51. DOI: 10.1016/j.ejso.2006.10.008. View

Kim H, Jang J, Yoon Y, Park S, Kwon W, Kim S . Does adjuvant treatment improve prognosis after curative resection of ampulla of Vater carcinoma? A multicenter retrospective study. J Hepatobiliary Pancreat Sci. 2020; 27(10):721-730. DOI: 10.1002/jhbp.801. View

Ecker B, Vollmer Jr C, Behrman S, Allegrini V, Aversa J, Ball C . Role of Adjuvant Multimodality Therapy After Curative-Intent Resection of Ampullary Carcinoma. JAMA Surg. 2019; 154(8):706-714. PMC: 6547142. DOI: 10.1001/jamasurg.2019.1170. View

10.

OConnell J, Maggard M, Manunga Jr J, Tomlinson J, Reber H, Ko C . Survival after resection of ampullary carcinoma: a national population-based study. Ann Surg Oncol. 2008; 15(7):1820-7. DOI: 10.1245/s10434-008-9886-1. View

11.

Jin Z, Hartgers M, Sanhueza C, Shubert C, Alberts S, Truty M . Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. Eur J Surg Oncol. 2018; 44(5):677-683. DOI: 10.1016/j.ejso.2018.02.008. View

12.

Al Abbas A, Falvello V, Zenati M, Mani A, Hogg M, Zeh 3rd H . Impact of adjuvant chemotherapy regimen on survival outcomes in immunohistochemical subtypes of ampullary carcinoma. J Surg Oncol. 2019; 121(2):322-329. DOI: 10.1002/jso.25808. View

13.

Chang D, Jamieson N, Johns A, Scarlett C, Pajic M, Chou A . Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol. 2013; 31(10):1348-56. DOI: 10.1200/JCO.2012.46.8868. View

14.

Zhao W, Wang B, Zhao A, Tian Q, Zhang L, Wang L . The role of radiotherapy in patients with resected ampullary carcinoma: findings based on the SEER database. HPB (Oxford). 2019; 21(11):1535-1540. DOI: 10.1016/j.hpb.2019.03.369. View